Printable View
Daily Market Commentary for March 12, 2014
OXiGENE, Inc. (OXGN-Nasdaq) announced late Tuesday, positive results from a randomized Phase 2 clinical trial evaluating Avastin(R) (bevacizumab) with or without ZYBRESTAT(R) (fosbretabulin; CA4P) to treat patients with recurrent ovarian cancer.
Read More at:http://www.millennium-traders.com/ne...ommentary.aspx
Thanks for reading
Millennium-Traders.Com
http://www.millennium-traders.com
It was classified as a "dead cat bounce" (down big yesterday but up big today) candidate. In addition to specific proprietary factors, OxiGene is also such a stock because it went down 5.9 but then up 3.2. I would still hold on if I were invested in this because I think it is going to come back before too long.
Проект платит
Инвест Планы:
Реф.программа 10%-4%-2%
Начисление процентов каждую секунду.
Вывод процентов и депозита в любой момент!
Проект платит
Инвест Планы:
Планы для инвестиций:
Basic 134% за 96 часов / от $5 до $300 (1.39 % в час)
Advanced 127% за 72 часов / от $50 до $1000 (1,76% в час)
Pro 119% за 48 часа / от $100 до $3000 (2.48% в час)
Royal 110% за 24 часов / от $250 до $10000 (4,58 % в час)
Реф.программа 10%-4%-2%
Начисление процентов каждый час
Вывод процентов и депозита в любой момент!
http://elite-house.biz/?ref=Nastya